Last reviewed · How we verify
AUTOLOGOUS CULTURED CHONDROCYTES
At a glance
| Generic name | AUTOLOGOUS CULTURED CHONDROCYTES |
|---|---|
| Drug class | Autologous Cultured Cell [EPC] |
| Phase | FDA-approved |
| First approval | 2009 |
Approved indications
Common side effects
- arthralgia
- back pain
- joint swelling
- joint effusion
- cartilage injury
- ligament sprain
- procedural pain
- treatment failure
Key clinical trials
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Implantation of Engineered Cartilage Grafts for Treatment of Patellofemoral Osteoarthritis Versus Surgical Comparators. (PHASE2)
- Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee (NA)
- A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle (PHASE3)
- The Biomechanical Outcomes of Autologous Chondrocyte Implantation
- Clinical Trial for the Regeneration of Cartilage Lesions in the Knee (NA)
- A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PHASE3)
- Autologous Cartilage Implantation vs Arthroscopic Debridement (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AUTOLOGOUS CULTURED CHONDROCYTES CI brief — competitive landscape report
- AUTOLOGOUS CULTURED CHONDROCYTES updates RSS · CI watch RSS